ChemoCentryx initiate Phase I trial of CCR9 antagonist CCX025

ChemoCentryx have initiated a Phase I clinical trial of CCX025, a CCR9 antagonist

Evotec initiate Phase I trial with P2X7 Antagonist

Evotec have initiated a Phase I clinical study of its proprietary, small molecule P2X7 receptor antagonist

Orexigens naltrexone SR shows efficacy in Phase I

Data presented at the Obesity Society Annual Scientific Meeting show Orexigen Therapeutic’s sustained release formulation of naltrexone, Contrave, achieved key objectives (lowered naltrexone Cmax, increased Tmax, comparable AUC) in two Phase 1 clinical trials.

Suven begin Phase I trials of 5-HT6 antagonist SUVN-502

Suven are to begin Phase I trials of 5-HT6 antagonist SUVN-502 intended for the treatment of Alzheimer’s disease.

Oxford BioMedicas gene therapy ProSavin effective in parkinsons

Oxford BioMedica  have announced promising results from the Phase I/II trial of its gene therapy, ProSavin, for the treatment of Parkinson’s disease. It delivers three genes required to convert cells that normally do not produce dopamine into cells that do.

Evotec/Pfizer initiate Phase I trial of VR1 antagonist

Evotec AG have announced the initiation of a Phase I clinical trial of a small molecule VR1 (vanilloid receptor 1) antagonist in collaboration with Pfizer

Phase I data show Theravance LAMA GSK1160724/TD-4208 safe in COPD patients

Theravance have announced Phase 1 data showing its long acting muscarinic antagonist (LAMA), GSK1160724/TD-4208 to be safe and well tolerated in the treatment of chronic obstructive pulmonary disease (COPD). Partner GSK have, however, informed Theravance that it intends to return the LAMA program to Theravance because the current formulation of TD-4208 is incompatible with GSK’s [...]

Glenmarks CB2 agonist GRC 10693 to enter phase I trials

Glenmark Pharmaceuticals have announced that its CB2 agonist GRC-10693 is entering Phase I trials for neuropathic, osteoarthritis and other inflammatory pain.

Mithridion commences Phase I Trial of MCD-386 for Alzheimer’s Disease

Mithridion has commenced a Phase I clinical trial of its investigational drug MCD-386 in Alzheimers. MCD-386 appears to activate of muscarinic M1 type receptor subtypes.

Arenas APD-791 in Phase Ib for Arterial Thrombosis

Arenas APD-791 has been found to be well tolerated in a Phase Ib trial for Arterial Thrombosis. The drug dose-dependently inhibited of serotonin-mediated amplification of platelet aggregation